Contact Information 
Address (Office) E12-4010 Joong Sup Shim
(Lab) N22-2027
Phone (Office) 8822 4990
(Lab) 8822 4217
Fax 8822 2314
Ph.D. Dept. Bioscience & Biotechnology, Sejong University, Korea (2000-2004)
M.S. Dept. Applied Biology, Dongguk University, Korea (1998-2000)
B.S. Dept. Biology, Dongguk University, Korea (1990-1998)
2013-present Assistant Professor, Faculty of Health Sciences, University of Macau
2011-2013 Research Associate, Dept. Pharmacology & Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
2006-2011 Postdoctoral Fellow, Dept. Pharmacology & Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
2005-2006 Research Scientist, Biotechnology Industrialization Institute, Yonsei University, Seoul, Korea
2004-2005 Lecturer, Dept. Bioscience & Biotechnology, Sejong University, Seoul, Korea
2000-2001 Research Assistant, Dept. Bioscience & Biotechnology, Sejong University, Seoul, Korea
Research Interests
My research interest is to discover novel and selective anticancer drugs for clinical use. We have adopted the drug repositioning into anticancer drug discovery and development process to improve the efficiency and to reduce cost, time and potential risk of failure associated with the process. The study will involve screening of the clinical drug library (Johns Hopkins Drug Library, JHDL) using uniquely established screening assay platforms, studying the mechanism of the potential drug candidates through chemical genetic approaches and preclinical testing of the drug candidates using animal models. To maximize opportunity to discover selective anticancer drugs, we will continuously search for new cancer-specific drug targets using genetic screens. Following research aims will be pursued in this laboratory:
1. Drug repositioning using JHDL
2. Discovery, mechanistic study and preclinical testing of angiogenesis inhibitors
3. Identification of cancer specific drug targets using synthetic lethality screening
Representative Publications
  1. Yang EJ, Wu C, Liu Y, Lv J, Shim JS*. Revisiting non-cancer drugs for cancer therapy. Curr Top Med Chem, 2016;16(19):2144-55.
  2. Shim JS, Li RJ, Bumpus NN, Head SA, Kumar K,Yang EJ, Lv J, Shi W, Liu JO, Divergence of anti-angiogenic activity and hepatotoxicity of different stereoisomers of itraconazole, Clin Cancer Res, 2016 Jun 1;22(11):2709-20.
  3. Head SA, Shi WQ, Zhao L, Gorshkov K, Pasunooti KK, Chen Y, Deng Z, Li RJ, Shim JS, Tan W, Hartung T, Zhang J, Zhao Y, Colombini M, Liu JO. The antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proc Natl Acad Sci USA, 2015 Dec 29;112(52):E7276-85.
  4. Wang G, Rajpurohit SK, Delaspre F, Walker SL, White DT, Ceasrine A, Kuruvilla R, Li RJ, Shim JS, Liu JO, Parsons MJ, Mumm JS. First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic β-cell mass. eLife, 2015 Jul 28;4.
  5. Lv J and Shim JS*. Existing drugs and their application in drug discovery targeting cancer stem cells. Arch Pharm Res, 2015; 38(9):1617-26.
  6. Kim NH, Pham NB, Quinn RJ, Shim JS, Cho H, Cho SM, Park SW, Kim JH, Seok SH, Oh JW, Kwon HJ. The small molecule R-(-)-β-O-methylsynephrine binds to nucleoporin 153 kDa and inhibits angiogenesis. Int J Biol Sci, 2015; 11(9):1088-99.
  7. Shim JS*, Li RJ, Lv J, Head SA, Yang EJ, Liu JO*. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism. Cancer Lett, 2015; 362(1):106-15.
  8. Wang M1, Shim JS1, Li RJ1, Dang Y, He Q, Das M, Liu JO. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer. Br J Pharmacol, 2014; 171(19):4478-89.
  9. Park H1, Shim JS1, Kim BS, Jung HJ, Huh TL, Kwon HJ. Purpurin inhibits adipocyte-derived leucine aminopeptidase and angiogenesis in a zebrafish model. Biochem Biophys Res Comm, 2014; 450(1):561-7.
  10. Shim JS* and Liu JO*. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci, 2014; 10(7):654-63.
  11. Zhang F, Bhat S, Gabelli SB, Chen X, Miller MS, Nacev BA, Cheng YL, Meyers DJ, Tenney K, Shim JS, Crews P, Amzel LM, Ma D, Liu JO. Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells. J Med Chem, 2013; 56(10):3996-4016.
  12. Choi SM, Kim Y, Shim JS, Park JT, Wang RH, Leach SD, Liu JO, Deng CX, Ye Z, Jang YY. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology, 2013; 57(6):2458-68.
  13. Kamiyama H, Rauenzahn S, Shim JS, Karikari CA, Feldmann G, Hua L, Kamiyama M, Schuler FW, Lin MT, Beaty RM, Karanam B, Liang H, Mullendore ME, Mo G, Hidalgo M, Jaffee E, Hruban RH, Jinnah HA, Roden RB, Jimeno A, Liu JO, Maitra A, Eshleman JR. Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res, 2013; 19(5):1139-46.
  14. Shim JS, Rao R, Beebe K, Neckers L, Han I, Nahta R and Liu JO. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst, 2012; 104(20):1576-90.
  15. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D. Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP. Gene Dev, 2012; 26(12): 1300-1305.
  16. Rovira M, Huang W, Yusuff S, Shim JS, Ferrante AA, Liu JO and Parsons MJ. Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation. Proc Natl Acad Sci USA, 2011; 108(48): 19264-19269.
  17. Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E and Nelson WG. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov, 2011; 1(1): 68-77, Inaugural Issue.
  18. Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, Dhara S, Han KC, Chong CR, Pomper MG, So A and Liu JO. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst, 2010; 102(24): 1855-1873.
  19. Jung HJ, Kim JH, Shim JS and Kwon HJ. A novel Ca2+/calmodulin antagonist HBC inhibits angiogenesis and down-regulates hypoxia-inducible factor. J Biol Chem, 2010; 285(33): 25867-25874.
  20. Jung HJ1, Shim JS1, Lee J, Song YM, Park KC, Choi SH, Kim ND, Yoon JH, Mungai PT, Schumacker PT and Kwon HJ. Terpestacin inhibits tumor angiogenesis by targeting UQCRB of mitochondrial complex III and suppressing hypoxia-induced ROS production and cellular oxygen sensing. J Biol Chem, 2010; 285(15): 11584-11595.
  21. Jung HJ, Shim JS, Suh YG, Kim YM, Ono M and Kwon HJ. Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid. Cancer Sci, 2007; 98(12): 1943-1948.
  22. Shim JS and Kwon HJ. Chemical genetics for therapeutic target mining. Expert Opin Ther Targets, 2004; 8(6): 653-661.
  23. Shim JS, Lee J, Park HJ, Park SJ, and Kwon HJ. A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function. Chem Biol, 2004; 11: 1455-1463.
  24. Shim JS, Kim DH, and Kwon HJ. Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells. Oncogene, 2004; 23(9): 1704-1711.
  25. Shim JS, Lee HS, Shin J, and Kwon HJ. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett, 2004; 203(2):163-169.
  26. Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, Park HJ, Shim BS, Choi SH, and Kwon HJ. Irreversible inhibition of CD13/aminopeptidase N by the anti-angiogenic agent curcumin. Chem Biol, 2003; 10: 695-704.

*Corresponding Author

International patent: WO/2010/042163 – Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders. Liu JO, Shim JS, Chong CR, and Bhat S. 04/15/2010
Korea patent: 1006410760000 – A novel aminopeptidase N Inhibitor. Kwon HJ, Lee J and Shim JS. 10/25/2006
Korea patent: 1006046970000 – A novel calmodulin antagonist and an immunosuppressive agent comprising thereof. Kwon HJ, Shim JS and Lee J. 07/19/2006
International patent: WO/2003/105751 – Novel curcumin derivatives. Kwon HJ, Shim JS, Kim JH, Choi SH, Shin JH and Rho JR. 12/24/2003
06/25/2011 Young Investigator Award in “2011 KSEA/KASBP Northeast Regional Conference and Bio Fair”, Edison, NJ, USA
05/25/2004 Best Poster Award in “The 61st Annual Meeting 2004” of the Korean Society for Biochemistry and Molecular Biology, Seoul, Korea
10/18/2001 Best Poster Award in “The Annual Meeting 2001” of the Korean Society for Biochemistry and Molecular Biology, Seoul, Korea
Professional Activities
2010-present Member of the American Chemical Society (ACS)
2011-2012 Vice President of the Baltimore Life Scientist Association (BLSA)
2011-2013 Member of the Korean-American Scientists and Engineers Association (KSEA)
2011-2013 Member of the Korean-American Professional Community in Biotechnology and Pharmaceuticals (KASBP)